Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7625803 | 0.93 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL6900662 | 0.91 | LTB4R (0.84) | LTB4RLTB4R2 | |
| SCHEMBL6968006 | 0.89 | LTB4R (0.80) | LTB4RLTB4R2 | |
| SCHEMBL6755957 | 0.89 | LTB4R (0.80) | LTB4RLTB4R2 | |
| SCHEMBL6965405 | 0.86 | LTB4R (0.76) | LTB4RLTB4R2 | |
| SCHEMBL6759556 | 0.86 | LTB4R (0.75) | LTB4RLTB4R2 | |
| SCHEMBL6759812 | 0.86 | LTB4R (0.75) | LTB4RLTB4R2 | |
| SCHEMBL6370354 | 0.86 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL8650764 | 0.86 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL6756029 | 0.86 | LTB4R (0.74) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933272-B1 | Use of non-peptidyl compounds for the treatment of insulin related ailments | HELMERHORST ERIK (AU) | 2005-08-23 | — | — | US | claimed |
| EP-1115422-A4 | USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS | UNIV CURTIN TECH (AU) | 2003-01-29 | — | — | EP | claimed |
| CN-1390139-A | Oncolytic combinations for the treatment of cancer | LILLY CO ELI (US) | 2003-01-08 | — | — | CN | claimed |
| EP-1115422-A1 | USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2001-07-18 | — | — | EP | claimed |
| WO-2000016798-A1 | USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2000-03-30 | — | — | WO | claimed |
| EP-0735870-A4 | USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 1998-08-19 | — | — | EP | claimed |
| EP-0735870-A1 | USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| US-5563164-A | TREATING ARTHRITIS, PSORIASIS, ASTHMA, INFLAMMATORY BOWEL DISEASE, OR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | claimed |
| US-5478857-A | Administering inhibitor of phospholipase A2 | ELI LILLY AND COMPANY (US) | 1995-12-26 | — | — | US | claimed |
| WO-1995017183-A1 | USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| US-6933272-B1 | Use of non-peptidyl compounds for the treatment of insulin related ailments | HELMERHORST ERIK (AU) | 2005-08-23 | — | — | US | disclosed |
| WO-1996006604-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | disclosed |
| US-5478857-A | Administering inhibitor of phospholipase A2 | ELI LILLY AND COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995017183-A1 | USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | LTB4R 5/4885LTB4R2 3/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | LTB4R 5/4885LTB4R2 3/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | LTB4R 5/4885LTB4R2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.